Chemical Component Summary

Namebenztropine
Identifiers(1~{S},5~{R})-3-(diphenylmethyl)oxy-8-methyl-8-azabicyclo[3.2.1]octane
FormulaC21 H25 N O
Molecular Weight307.429
TypeNON-POLYMER
Isomeric SMILESCN1[C@@H]2CC[C@H]1CC(C2)OC(c3ccccc3)c4ccccc4
InChIInChI=1S/C21H25NO/c1-22-18-12-13-19(22)15-20(14-18)23-21(16-8-4-2-5-9-16)17-10-6-3-7-11-17/h2-11,18-21H,12-15H2,1H3/t18-,19+,20+
InChIKeyGIJXKZJWITVLHI-PMOLBWCYSA-N

Chemical Details

Formal Charge0
Atom Count48
Chiral Atom Count3
Bond Count51
Aromatic Bond Count12

Drug Info: DrugBank

DrugBank IDDB00245 
NameBenzatropine
Groups approved
DescriptionBenztropine, with the chemical formula 3alpha-diphenylmethoxytropane, is a tropane-based dopamine inhibitor used for the symptomatic treatment of Parkinson's disease. It is a combination molecule between a tropane ring, similar to cocaine, and a diphenyl ether from the dialkylpiperazines determined to be a dopamine uptake inhibitor since 1970. The generation of structure-activity relationships proved that benztropine derivatives with the presence of a chlorine substituent in the para position in one of the phenyl rings produces an increased potency for dopamine uptake inhibition as well as a decreased inhibition of serotonin and norepinephrine.[A37914] Benztropine was developed by USL Pharma and officially approved by the FDA on 1996.[L5500]
Synonyms
  • Tropine benzohydryl ether
  • Benzatropina
  • Benzatropine mesylate
  • Benzatropine
  • Benzatropinum
Brand Names
  • Vpi-benztropine
  • Benztropine
  • Cogentin
  • Pdp-benztropine
  • Benztropine Mesylate
IndicationBenztropine is indicated to be used as an adjunct in the therapy of all forms of parkinsonism. It can also be used for the control of extrapyramidal disorders due to neuroleptic drugs.[T203] The extrapyramidal symptoms are defined as drug-induced disorders that include symptoms of dystonia, akathisia, parkinsonism, bradykinesia, tremors, and dyskinesia.[A175120] Parkinsonism is a general term that refers to the group of neurological disorders that produce symptoms similar to Parkinson's disease such as tremors, slow movement, and stiffness. The parkinsonism includes a large number of disorders and some of them have not been clearly defined.[L5509]
Categories
  • Agents producing tachycardia
  • Alkaloids
  • Anti-Dyskinesia Agents
  • Anti-Parkinson Drugs
  • Anticholinergic Agents
ATC-CodeN04AC01
CAS number86-13-5

Drug Targets

NameTarget SequencePharmacological ActionActions
Muscarinic acetylcholine receptor M1MNTSAPPAVSPNITVLAPGKGPWQVAFIGITTGLLSLATVTGNLLVLISF...unknownantagonist
Sodium-dependent dopamine transporterMSKSKCSVGLMSSVVAPAKEPNAVGPKEVELILVKEQNGVQLTSSTLTNP...unknowninhibitor
Histamine H1 receptorMSLPNSSCLLEDKMCEGNKTTMASPQLMPLVVVLSTICLVTVGLNLLVLY...unknownantagonist
Sodium-dependent serotonin transporterMETTPLNSQKQLSACEDGEDCQENGVLQKVVPTPGDKVESGQISNGYSAV...unknowninhibitor
Sodium-dependent noradrenaline transporterMLLARMNPQVQPENNGADTGPEQPLRARKTAELLVVKERNGVQCLLAPRD...unknowninhibitor
View More
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682

Related Resource References

Resource NameReference
CCDC/CSD BZTRMS, GOMREF